作者: P Zoldhelyi , M W Webster , V Fuster , D E Grill , D Gaspar
关键词:
摘要: BACKGROUNDBecause the specific antithrombin hirudin prevents platelet-rich arterial thrombus and accelerates thrombolysis in a variety of animal models, it has promise as antithrombotic therapy. We therefore studied half-life, effect on anticoagulant parameters, safety patients with coronary artery disease.METHODS AND RESULTSThirty-eight men 1 woman (age [mean +/- SD], 60.4 6.9 years) angiographic disease were allocated single-blind ascending dosage study to 6-hour i.v. infusion recombinant (CGP 39,393) or matching placebo. The median terminal half-life for hirudin, measured by ELISA, was 2.7, 2.3, 2.9, 3.1, 2.0 hours 0.02, 0.05, 0.1, 0.2, 0.3 mg.kg-1 x h-1 groups, respectively. Activated partial thromboplastin times (aPTT) at 3, 4, 6 averaged into plateau value. aPTT plateau-to-baseline ratios 1.5 2.3 2.7 2.9 respectively, infused 0.0...